CBER chief forecasts better global regulatory convergence around cell and gene therapies

Zachary Brennan

Senior Editor

Peter Marks, who’s responsible for the FDA’s oversight of cell and gene therapies, expects regulators around the world will be better at collaborating on gene …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CBER chief forecasts better global regulatory convergence around cell and gene therapies

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Updated: Bristol Myers touts LAG-3 strategy in lung cancer, but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing

CBER chief fore­casts bet­ter glob­al reg­u­la­to­ry con­ver­gence around cell and gene ther­a­pies

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

CBER chief forecasts better global regulatory convergence around cell and gene therapies